Evaluating the glycemic effects of Dolutegravir and its predictors among people living with HIV in Uganda: A prospective cohort study.

Simple item page
dc.contributor.authorAnkunda, Collins
dc.contributor.authorAgolor, Curthbert
dc.contributor.authorKaramagi, Yvonne
dc.contributor.authorNakubulwa, Susan
dc.contributor.authorNamasambi, Sharon
dc.contributor.authorKasamba, Ivan
dc.contributor.authorChristopher, Semei Mukama
dc.contributor.authorKukundakwe, Patience
dc.contributor.authorOdiit, Mary
dc.contributor.authorMubangizi, Ivan
dc.contributor.authorEmunyu, Jude
dc.contributor.authorKesi, Diana Nakitto
dc.contributor.authorNambasa, Victoria
dc.contributor.authorNdagije, Helen Byomire
dc.contributor.authorMukasa, Barbara
dc.date.accessioned2024-10-16T10:56:36Z
dc.date.available2024-10-16T10:56:36Z
dc.date.issued2024-10
dc.description.abstractAbstract Introduction Dolutegravir (DTG), a key component of the recommended HIV treatment regimens in Uganda, has been associated with hyperglycemia. We evaluated its influence on hyperglycemia risk to create a hyperglycemia risk stratification tool for patient monitoring. Methods We conducted a prospective cohort study at three sites with 628 HIV patients on Tenofovir Disoproxyl Fumarate, Lamivudine, and Dolutegravir (TLD). Participants included both Nucleoside reverse transcriptase inhibitors-experienced (exposed) and ART-naïve (non-exposed) groups. Follow-ups occurred every six months with Random Blood Sugar(RBS)every three months. Participants with RBS ≥ 7 mmol/L were classified as hyperglycemic and underwent HbA1c testing, confirming diabetes with a 6.5% cut-off. Results The study found a hyperglycemia incidence rate of 24.5 cases per 100 person-years (95% CI: 19.3-31.1) and a diabetes incidence rate of 5.8 cases per 100 person-years (95% CI: 3.6-9.3). Hyperglycemia incidence was slightly lower in non-exposed (20.8 cases per 100 person-years) vs. exposed groups (25.2 cases per 100 person-years). Multivariable analysis indicated a trend towards lower hyperglycemia risk in non-exposed (adjusted HR = 0.78, 95% CI: 0.37-1.66, p = 0.52) and substantially lower diabetes incidence (adjusted HR = 0.34, 95% CI: 0.04-2.82, p = 0.32). Significant factors for hyperglycemia included age (p < 0.001), study site (p < 0.001), and DTG-based ART duration (p = 0.02). Conclusion Our study showed an increased incidence of hyperglycemia with age, study site, and duration of DTG exposure in HIV patients on TLD. We suggest integrated screening and care for hyperglycemia and diabetes in HIV services, especially when initiating DTG regimens.
dc.identifier.citationAnkunda, Collins, Curthbert Agolor, Yvonne Karamagi, et al. 'Evaluating the Glycemic Effects of Dolutegravir and its Predictors among People Living with HIV in Uganda: A Prospective Cohort Study', Open Forum Infectious Diseases, (2024), .
dc.identifier.issnISSN 2328-8957
dc.identifier.issnEISSN 2328-8957
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9656
dc.language.isoen
dc.publisherOpen Forum Infectious Diseases
dc.titleEvaluating the glycemic effects of Dolutegravir and its predictors among people living with HIV in Uganda: A prospective cohort study.
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ofae596.pdf
Size:
650.48 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences